CA3103175A1 - Microrna inhibitors for use in treating metabolic diseases - Google Patents

Microrna inhibitors for use in treating metabolic diseases Download PDF

Info

Publication number
CA3103175A1
CA3103175A1 CA3103175A CA3103175A CA3103175A1 CA 3103175 A1 CA3103175 A1 CA 3103175A1 CA 3103175 A CA3103175 A CA 3103175A CA 3103175 A CA3103175 A CA 3103175A CA 3103175 A1 CA3103175 A1 CA 3103175A1
Authority
CA
Canada
Prior art keywords
mir
inhibitor
fragment
composition
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3103175A
Other languages
English (en)
French (fr)
Inventor
Stephan Herzig
Manuel Gil LOZANO
Tobias Schafmeier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum München
Original Assignee
Helmholtz Zentrum München
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum München filed Critical Helmholtz Zentrum München
Publication of CA3103175A1 publication Critical patent/CA3103175A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3103175A 2018-09-11 2019-09-10 Microrna inhibitors for use in treating metabolic diseases Pending CA3103175A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LULU100927 2018-09-11
LU100927 2018-09-11
PCT/EP2019/074056 WO2020053186A1 (en) 2018-09-11 2019-09-10 Microrna inhibitors for use in treating metabolic diseases

Publications (1)

Publication Number Publication Date
CA3103175A1 true CA3103175A1 (en) 2020-03-19

Family

ID=63998726

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3103175A Pending CA3103175A1 (en) 2018-09-11 2019-09-10 Microrna inhibitors for use in treating metabolic diseases

Country Status (7)

Country Link
US (1) US12584126B2 (cg-RX-API-DMAC10.html)
EP (1) EP3850099B1 (cg-RX-API-DMAC10.html)
JP (3) JP7530836B2 (cg-RX-API-DMAC10.html)
CN (1) CN112654705B (cg-RX-API-DMAC10.html)
CA (1) CA3103175A1 (cg-RX-API-DMAC10.html)
DK (1) DK3850099T3 (cg-RX-API-DMAC10.html)
WO (1) WO2020053186A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7530836B2 (ja) 2018-09-11 2024-08-08 ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー 代謝性疾患の処置において使用するためのマイクロrnaインヒビター
CN111228291B (zh) * 2020-03-20 2020-10-02 军事科学院军事医学研究院环境医学与作业医学研究所 miR-541在制备抗神经元细胞缺氧损伤药物中的应用及药物
CN121818694B (zh) * 2025-12-23 2026-07-28 内蒙古大学 改善胰岛素抵抗的miR-3963在制备药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
WO2014074874A1 (en) * 2012-11-09 2014-05-15 Regents Of The University Of Minnesota Osteosarcoma diagnostic and prognostic methods
EP2868746A1 (en) 2013-10-29 2015-05-06 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Micrornas modulating the effect of glucocorticoid signaling
WO2016065001A1 (en) * 2014-10-21 2016-04-28 University Of Massachusetts Recombinant aav variants and uses thereof
CN106267207A (zh) * 2015-06-05 2017-01-04 昆山彭济凯丰生物科技有限公司 通过miR-96进行减肥、降血糖和降血脂的方法和药物及其应用
WO2019102268A1 (en) * 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
JP7530836B2 (ja) 2018-09-11 2024-08-08 ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー 代謝性疾患の処置において使用するためのマイクロrnaインヒビター

Also Published As

Publication number Publication date
JP7893574B2 (ja) 2026-07-22
WO2020053186A1 (en) 2020-03-19
EP3850099B1 (en) 2025-09-03
CN112654705B (zh) 2024-07-02
JP2021535079A (ja) 2021-12-16
JP2026091891A (ja) 2026-06-04
CN112654705A (zh) 2021-04-13
JP7530836B2 (ja) 2024-08-08
US20210254067A1 (en) 2021-08-19
EP3850099A1 (en) 2021-07-21
JP2024073525A (ja) 2024-05-29
DK3850099T3 (da) 2025-10-13
US12584126B2 (en) 2026-03-24

Similar Documents

Publication Publication Date Title
AU2012322788B2 (en) Micrornas in neurodegenerative disorders
EP3354734B1 (en) Oligonucleotide-based inhibitors comprising locked nucleic acid motif
JP2024073525A (ja) 代謝性疾患の処置において使用するためのマイクロrnaインヒビター
EP2208499A1 (en) Nucleic acid capable of regulating the proliferation of cell
EP2298359A1 (en) Nucleic acid capable of controlling degranulation of mast cell
CA3133704A1 (en) Rna editing inhibitors and methods of use
US20090136957A1 (en) Methods and compositions for regulating cell cycle progression via the miR-106B family
EP2683411B1 (en) Methods of using microrna-26a to promote angiogenesis
Tan et al. MicroRNA-based therapy in pain medicine: Current progress and future prospects
WO2010120969A1 (en) Targeting of the mir-30 family and let-7 family as a treatment for heart disease
KR20150036140A (ko) 마이크로RNAs의 MIR-15 패밀리의 억제제
EP3198012A1 (en) Rna-modulating agents
Durso et al. Chemical modifications in the seed region of miRNAs 221/222 increase the silencing performances in gastrointestinal stromal tumor cells
US20090023670A1 (en) Regulation of Transgene Expression by RNA Interference
JP2009516710A (ja) eIF4E−BP2の発現のモジュレート
EP2175023A1 (en) Anti-tumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA
WO2021030867A1 (en) Method of modulating adiposity
CN120905229B (zh) 一种靶向INHBE基因表达的siRNA及其缀合物和用途
JP7017193B2 (ja) Rna作用抑制剤及びその利用
WO2017096053A2 (en) Methods of reducing expression of x-inactivation escapee genes and autosomal genes
WO2025195381A1 (zh) 一种靶向INHBE基因表达的siRNA及其缀合物和用途
WO2012142199A1 (en) Mirnas dysregulated in ewing sarcoma
WO2011010737A1 (ja) マイクロrna切断用のガイド核酸
Soukup et al. MicroRNA-513 Regulates B7-H1 Translation
HK1201294B (en) Micrornas in neurodegenerative disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220926

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20240828

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240904

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240904

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240904

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250901

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250901

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260113

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20260217

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260429

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260429